.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,300,664

« Back to Dashboard

Claims for Patent: 7,300,664

Title:Vaginally administrable progesterone-containing tablets and method for preparing same
Abstract:There is provided a method for preparing a tablet for the vaginal administration of progesterone for systemic use, comprising the steps of: slowly mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, whereby to obtain wetted micronized progesterone; drying said wetted, micronized progesterone to a humidity content of substantially 0%, whereby to form substantially dry micronized progesterone; mixing said substantially dry micronized progesterone with other pharmaceutically acceptable excipients or diluents therefor; and forming a tablet by direct compaction of said substantially dry micronized progesterone which has been mixed with said other pharmaceutically acceptable excipients or diluents therefor. Tablets so prepared, as well as a tablet comprising between about 6 to 20 wt. % progesterone and between about 5 to 12 wt. % effervescent, are also provided.
Inventor(s): Jossifoff; Azariah (Ramat Gan, IL)
Assignee: Ferring B.V. (Hoofdorp, NL)
Application Number:09/856,417
Patent Claims: 1. A method of delivering progesterone to a female patient, comprising placing in the vagina of said patient a tablet consisting of progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent, and retaining said tablet in the vagina for a time efficacious to deliver said progesterone to said patient.

2. A method according to claim 1, wherein the progesterone in said tablet is present in an amount of at least 50 mg.

3. A method according to claim 2, wherein said placing of tablet is effected as part of a twice-daily dosing regimen.

4. The method of claim 2, wherein the progesterone in said tablet is present in an amount of at least about 50 mg.

5. The method of claim 1, wherein the progesterone in said tablet is present in an amount of at least about 100 mg.

6. The method of claim 1, wherein the effervescent in the tablet is present in an amount of about 5% to about 12% by weight of the tablet.

7. The method of claim 6, wherein the effervescent in the tablet is present in an amount of about 8% by weight of the tablet.

8. The method of claim 1, wherein said placing of said tablet is effected as part of a twice-daily dosing regimen.

9. The method of claim 1, wherein the progesterone is micronized progesterone.

10. A method of delivering progesterone to a female patient, comprising placing in the vagina of said patient a tablet consisting of progesterone, a pharmaceutically acceptable excipient or diluent, and an effervescent, wherein said tablet is prepared by the steps of: (i) mixing water with progesterone to obtain wetted progesterone in the absence of pharmaceutically acceptable excipients or diluents; and drying said wetted progesterone to form dry progesterone; (ii) mixing said dry progesterone with (a) a pharmaceutically acceptable excipients or diluents and (b) an effervescent to form a mixture; and (iii) forming the tablet by direct compaction of said mixture, and retaining said tablet in said vagina until the tablet dissolves, wherein the tablet provides a T.sub.max upon dissolution of about three hours.

11. A method according to claim 10, wherein the progesterone in said tablet is present in an amount of at least 50 mg.

12. A method according to claim 10, wherein said placing of said tablet is effected as part of a twice daily dosing regiment.

13. The method of claim 10, wherein the progesterone is micronized progesterone.

14. The method of claim 10, wherein the progesterone in said tablet is present in an amount of about 100 mg.

15. A method of delivering progesterone to a female patient, which method comprises (a) placing in the vagina of the patient a vaginal tablet consisting of micronized progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent; and (b) permitting the tablet to dissolve in the vagina, the tablet providing a T.sub.max of about 3 hours upon dissolution.

16. A method of delivering progesterone to a female patient, comprising placing in the vagina of the patient a tablet consisting essentially of micronized progesterone, colloidal anhydrous silica, maize starch, povidone, lactose, adipic acid, sodium bicarbonate, magnesium stearate, and sodium lauryl sulfate.

17. The method of claim 16, wherein the tablet consists essentially of about 8 wt. % dry micronized progesterone, about 0.2 wt. % colloidal anhydrous silica, about 16.8 wt. % maize 1500 starch, about 4.0 wt. % povidone 30, about 60.8 wt. % lactose, about 4.5 wt. % adipic acid, about 3.4 wt. % sodium bicarbonate, about 1.8 wt. % magnesium stearate, and about 0.4 wt. % sodium lauryl sulfate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc